SBTX - SKINBIOTHERAPEUTICS - Share Chat

SkinBioTherapeutics Plc (AIM: SBT) is a UK-based life sciences company focused on developing proprietary technology based on the skin microbiome. Spun out of the University of Manchester, its core expertise lies in harnessing beneficial bacteria lysates to create products that support skin health.

The company’s flagship asset, SkinBiotix®, is a lysate designed to strengthen the skin barrier, improve hydration, and reduce inflammation. SkinBioTherapeutics operates a dual strategy: commercialising SkinBiotix® in the cosmetic sector through a strategic partnership with Croda International Plc, and advancing pharmaceutical applications. Its food supplement, AxisBiotix™, addresses the gut-skin axis for conditions like psoriasis, having shown promising results in user trials. The company is positioned in the growing microbiome-based health and beauty market.